News

  • August 31, 2021
    Luca Santarelli's VectivBio buys out small Massachusetts biotech, redoubling focus on metabolic disease

    https://endpts.com/luca-santarellis-vectivbio-buys-out-small-massachusetts-biotech-redoubling-focus-on-metabolic-disease/

  • May 12, 2021
    Recent news coverage relating to the close of our third fund:

    http://www.montrealintechnology.com/cti-life-sciences-new-fund/

    https://privatecapitaljournal.com/cti-life-sciences-fund-holds-100m-initial-close-for-3rd-fund/

    https://www.theglobeandmail.com/business/article-cti-raises-100-million-to-invest-in-early-stage-canadian-life-sciences/

    PE Hub

  • May 10, 2021
    CTI Life Sciences Fund Successfully Raises $100 Million As A First Tranche of its Third Venture Capital Fund

    Read Article

  • February 8, 2021
    Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis

    Read Article

  • February 3, 2021
    VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome

    Read Article

  • December 15, 2020
    Pfizer Doses First Patients as Part of Global Achondroplasia Phase 2 Development Program

    Read Article

  • November 4, 2020
    VectivBio Strengthens Business Development Capabilities with Key Appointments

    Read Article

  • June 8, 2020
    Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal

    Read Article

  • May 8, 2019
    Pfizer Acquires Clinical-Stage Biotech Therachon

    Read Article

  • September 4, 2018
    Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration

    Read Article

  • May 3, 2018
    Immunovaccine Inc. Has Applied to List its Common Shares on Nasdaq, Announces Reverse Stock Split

    Read Article

  • December 5, 2017
    Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium

    Read Article

  • November 13, 2017
    Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

    Read Article

  • July 27, 2017
    PreciThera, Inc. Completes $36M Series A Financing

    Read Article

  • April 27, 2017
    Zymeworks Announces Pricing of Initial Public Offering

    Read Article

  • March 29, 2017
    Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX

    Read Article

  • March 21, 2017
    SutroVax Announces Closing of $64M via Series B Financing

    Read Article

  • March 14, 2017
    CellAegis Devices Announces US$9.5 Million Financing to Support Clinical and Regulatory Advancement of its autoRIC® Device

    Read Article

  • November 14, 2016
    Profound Medical Corp. Completes Previously Announced $17.4M Bought Deal Offering of Common Shares

    Read Article

  • November 10, 2016
    Toronto’s Xagenic Inc. completes successful beta testing of X1 diagnostic system

    Read Article

  • November 7, 2016
    Immunovaccine’s Preclinical DPX-NEO Program Demonstrates Positive Anti-Cancer Activity

    Read Article

  • September 28, 2016
    Venous infers_Early work sufficient to attract $21M for Ilkos leg ulcers effort

    Read Article

  • June 8, 2016
    Immunovaccine Announces Closing of $8M Bought Deal Private Placement Financing

    Read Article

  • April 26, 2016
    Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies

    Read Article

  • April 26, 2016
    Zymeworks Names Diana Hausman, M.D. Chief Medical Officer

    Read Article

  • April 20, 2016
    DalCor raises $100M in series B

    Read Article

  • April 19, 2016
    Biotech upstart gambles $150M believing it can succeed after Big Pharmas failed on CETP

    Read Article

  • April 19, 2016
    With $150M in the bank, Dalcor seeks phase III success with dalcetrapib

    Read Article

  • April 19, 2016
    Startup Aims to Revive Failed Drug

    Read Article

  • April 19, 2016
    Xagenic readies X1 molecular diagnostic beta trials

    Read Article

  • March 23, 2016
    Zymeworks Completes Acquisition of Kairos Therapeutics Creating a Leader in Biologics Drug Discovery and Development

    Read Article

  • January 8, 2016
    Zymeworks Announces $61.5M Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics

    Read Article

  • November 9, 2015
    Investissement Québec invests 10M in CTI Life Sciences Fund II

    Read Article

  • August 11, 2015
    PHEMI Closes $12.2M Venture Financing

    Read Article

  • July 23, 2015
    SutroVax raises $22M in Series A

    Read Article

  • June 15, 2015
    XTuit Pharmaceuticals Closes $22M Series A Financing to Advance Novel Microenvironmental Modulators for Cancers and Fibrotic Disorders

    Read Article

  • May 6, 2015
    Impressive Industry Leaders Elected to BIOTECanada Board of Directors

    Read Article

  • April 9, 2015
    NEOMED Announces Appointment of Dr. Laurence Rulleau to its Board of Directors

    Read Article

  • January 21, 2015
    Zymeworks Announces Bi-Specific Antibody Collaboration with Celgene

    Read Article

  • January 15, 2015
    CTI Life Sciences successfully raises new C$ 134 Million venture capital fund

    Read Article

  • July 14, 2014
    Xagenic Announces Second Closing of $25.5M Series B Financing

    Read Article

  • July 12, 2013
    Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M

    Read Article

  • October 5, 2012
    Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec

    Read Article

  • February 10, 2012
    Closing of acquisition of Enobia by Alexion – Yet another successful portfolio exit for CTI Life Sciences Fund

    Read Article

  • January 30, 2012
    Xagenic Inc. Closes C$10M Series A Financing

    Read Article

  • December 28, 2011
    Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)

    Read Article

  • September 27, 2011
    Medicago Completes $25M Private Placement

    Read Article

  • August 29, 2011
    Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies

    Read Article

  • August 9, 2011
    Enobia Pharma Raises US $40 million

    Read Article

  • April 5, 2011
    Medicago Announces Closing of C$17.4 Million Equity Offering

    Read Article

  • June 30, 2010
    Sanofi-Aventis to acquire TargeGen Inc., a US biopharmaceutical company

    Read Article

  • June 29, 2010
    Zymeworks Closes C$3.2M Round of Financing

    Read Article

  • February 11, 2010
    Somnus Therapeutics Closes US$15M Series A Financing with CTI Life Sciences and Care Capital

    Read Article

  • December 29, 2009
    NeurAxon Announces Closing of Convertible Debenture Financing

    Read Article

  • August 10, 2009
    Enobia Pharma Inc. Raises US$50M from Current Investors in Series C Financing

    Read Article

  • June 23, 2009
    Zymeworks Closes C$3.4M Financing Round and Announces Changes to its Board of Directors

    Read Article

  • October 15, 2007
    Chlorion Pharma Inc. Closes C$6.0 million Financing Round

    Read Article

  • September 10, 2007
    Enobia Pharma Inc. Closes C$40.1 million Series B Financing Round

    Read Article

  • July 12, 2007
    TargeGen Inc. Closes $40.0M Series D Financing Round

    Read Article

  • October 4, 2006
    CTI Life Sciences Fund Will Invest $100 Million in Business Seeds and Start-ups

    Montreal, October 4, 2006 – The Minister of Economic Development, Innovation and Export Trade, Raymond Bachand, accompanied by the CEO of FIER Partners, L.P., Sylvie Pinsonnault and Ken Pastor, Senior Partner and Associate Director with CTI Capital, has announced an investment of $25 million by FIER Partners in the new CTI Life Sciences Fund.

    “With this new commitment, FIER Partners is making its first investment under the new technology company seed investment section that fills a substantial need in the venture capital market in Québec,” Mr. Bachand said. “I am particularly proud that this investment has contributed to setting up CTI Life Sciences Fund, a fund headed by a team of experienced experts that is backed by many other Québec investors,” Minister Bachand added.

    CTI Life Sciences Fund has been formed to offer venture capital to first-generation companies in life sciences operating in biotechnology, biopharmaceuticals and medical devices. “The support of FIER Partners and other institutional investors in Québec was crucial in the creation of this fund in Québec, dedicated solely to supporting the creation and development of companies involved in life sciences,” Ken Pastor, Senior Partner of CTI Life Sciences Fund, said.

    FIER Partners has invested $25 million in CTI Life Sciences Fund. The remaining capital of $75 million is being provided in particular by the Caisse de dépôt et placement du Québec, the Fonds de Solidarité du Québec, the Régime de rentes du mouvement Desjardins and partners of the fund, Jean-François Leprince, Richard Meadows, Ken Pastor and CTI Capital.

    “FIER Partners is very satisfied that it has contributed to the formation of this fund that aims to satisfy a substantial need for financing of companies in life sciences, particularly those at the seeding stage,” explained Sylvie Pinsonnault who added that the substantial capital of $100 million of CTI Life Sciences Fund will enable better development of companies that will receive investments throughout their growth phase.

    FIER Partners is one of three components of the Regional Economic Intervention Fund (FIER) set up at the government’s initiative. It consists of a limited partnership whose initial capitalization of $180 million is provided by IQ-FIER, a subsidiary of Investissement Québec, for $90 million, and by three tax-advantaged funds: the Fonds de solidarité FTQ ($50 million), Capital régional et coopératif Desjardins ($25 million) and Fondaction, the CSN development fund for cooperation and employment ($15 million).

    FIER Partners L.P. has $80 million available to support the creation of sector development funds that make equity or quasi-equity investments in start-up companies. The limited partnership contributes one dollar for every two dollars sourced from private investors, so that the total capitalization of the sector funds may ultimately reach $240 million. FIER Partners also has $60 million available to support funds that make technology company seed investments. Lastly, it has a $40-million envelope to support developmental projects, mainly in the regions.

    Minister Bachand thanked the partners who participated in the creation of CTI Life Sciences Fund. “By making use of effective levers such as FIER Partners and with the contribution of our largest institutional investors, the government intends to support economic sectors that will help Québec to improve its position in relation to global competition. With the addition of the expertise and vitality of our businesspeople, we have the ingredients needed for new companies in the knowledge-based economy to flourish, here and internationally and thus contribute to Québec’s economic prosperity,” Mr. Bachand concluded.